CYP19A1 and breast cancer: Based on multiple trials demonstrating improved breast cancer outcomes when compared to treatment with adjuvant tamoxifen, a third-generation aromatase inhibitor (AI) (anastrozole, letrozole, or exemestane) is generally the preferred adjuvant endocrine therapy for postmenopausal women with early stage HR + breast cancer (Francis et al., 2018).